tetano
Editor, Senior Moderator
BMJ Open
. 2023 Aug 7;13(8):e069858.
doi: 10.1136/bmjopen-2022-069858. Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol
Stefania Spila Alegiani[SUP] #[/SUP][SUP] 1 [/SUP], Cristina Morciano[SUP] #[/SUP][SUP] 1 [/SUP], Francesca Menniti-Ippolito[SUP] 1 [/SUP], Roberto Da Cas[SUP] 1 [/SUP], Patrizia Felicetti[SUP] 2 [/SUP], Pasquale Marchione[SUP] 2 [/SUP], Fiorella Petronzelli[SUP] 2 [/SUP], Anna Rosa Marra[SUP] 2 [/SUP], Marco Massari[SUP] 3 [/SUP]
Affiliations
Introduction: The purpose of TheShinISS-Vax|Flu study is to examine the association between influenza vaccines and adverse events requiring hospital admission or emergency care during the influenza vaccination campaigns 2021/2022 and 2022/2023 in Italy.
Methods and analysis: This is a Self-Controlled Case Series multiregional study using linked routinely collected data from regional healthcare databases of the participating regions. Study participants will be persons aged ≥6 months, unvaccinated or who have received influenza vaccine during the influenza vaccination campaigns in the seasons 2021/2022 and 2022/2023 in Italy and who have experienced the outcome of interest for the first time during the study period (1 September 2021-30 June 2022 and 1 September 2022-30 June 2023 for the first and second vaccination campaigns, respectively). Risk periods will be specifically defined for each outcome and further subdivided into periods of 7 days. The exposures will be the first or second dose of the influenza vaccines administered during the two vaccination campaigns. Statistical analysis will be conducted separately for the data of the two campaigns. Exposure risk period will be compared with baseline risk period defined as any time of observation out of the risk periods. The modified SCCS method will be applied to handle event-dependent exposure and mortality and fitted using unbiased estimating equations to estimate relative incidences and excess of cases per 100 000 vaccinated by dose, age, sex and type of vaccine. Calendar period will be included as time-varying confounder in the model, where appropriate.
Ethics and dissemination: The study received the approval from the National ethics committee for clinical trials of public research bodies and other national public institutions (PRE BIO CE n.0036723, 23/09/2022). Results will be published in peer-reviewed journals and reports in accordance with the publication policies of the Italian National Institute of Health and of the Italian Medicines Agency.
Keywords: epidemiology; public health; statistics & research methods.
. 2023 Aug 7;13(8):e069858.
doi: 10.1136/bmjopen-2022-069858. Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol
Stefania Spila Alegiani[SUP] #[/SUP][SUP] 1 [/SUP], Cristina Morciano[SUP] #[/SUP][SUP] 1 [/SUP], Francesca Menniti-Ippolito[SUP] 1 [/SUP], Roberto Da Cas[SUP] 1 [/SUP], Patrizia Felicetti[SUP] 2 [/SUP], Pasquale Marchione[SUP] 2 [/SUP], Fiorella Petronzelli[SUP] 2 [/SUP], Anna Rosa Marra[SUP] 2 [/SUP], Marco Massari[SUP] 3 [/SUP]
Affiliations
- PMID: 37550029
- DOI: 10.1136/bmjopen-2022-069858
Introduction: The purpose of TheShinISS-Vax|Flu study is to examine the association between influenza vaccines and adverse events requiring hospital admission or emergency care during the influenza vaccination campaigns 2021/2022 and 2022/2023 in Italy.
Methods and analysis: This is a Self-Controlled Case Series multiregional study using linked routinely collected data from regional healthcare databases of the participating regions. Study participants will be persons aged ≥6 months, unvaccinated or who have received influenza vaccine during the influenza vaccination campaigns in the seasons 2021/2022 and 2022/2023 in Italy and who have experienced the outcome of interest for the first time during the study period (1 September 2021-30 June 2022 and 1 September 2022-30 June 2023 for the first and second vaccination campaigns, respectively). Risk periods will be specifically defined for each outcome and further subdivided into periods of 7 days. The exposures will be the first or second dose of the influenza vaccines administered during the two vaccination campaigns. Statistical analysis will be conducted separately for the data of the two campaigns. Exposure risk period will be compared with baseline risk period defined as any time of observation out of the risk periods. The modified SCCS method will be applied to handle event-dependent exposure and mortality and fitted using unbiased estimating equations to estimate relative incidences and excess of cases per 100 000 vaccinated by dose, age, sex and type of vaccine. Calendar period will be included as time-varying confounder in the model, where appropriate.
Ethics and dissemination: The study received the approval from the National ethics committee for clinical trials of public research bodies and other national public institutions (PRE BIO CE n.0036723, 23/09/2022). Results will be published in peer-reviewed journals and reports in accordance with the publication policies of the Italian National Institute of Health and of the Italian Medicines Agency.
Keywords: epidemiology; public health; statistics & research methods.